Colin MS - Cross Country Chief Officer
| XXY Stock | EUR 17.10 0.10 0.58% |
Insider
Colin MS is Chief Officer of Cross Country Healthcare
| Age | 55 |
| Phone | 561 998 2232 |
| Web | https://www.crosscountryhealthcare.com |
Cross Country Management Efficiency
The company has return on total asset (ROA) of 0.2092 % which means that it generated a profit of $0.2092 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4994 %, meaning that it generated $0.4994 on every $100 dollars invested by stockholders. Cross Country's management efficiency ratios could be used to measure how well Cross Country manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | INSIDER Age | ||
| Koichi Mikami | Canon Marketing Japan | N/A | |
| Hatsumi Hirukawa | Canon Marketing Japan | N/A | |
| Akira Kanazawa | Canon Marketing Japan | N/A | |
| Minoru Mizoguchi | Canon Marketing Japan | N/A | |
| Tsuyoshi Osato | Canon Marketing Japan | N/A | |
| Masachika Adachi | Canon Marketing Japan | 63 | |
| Toshio Matsumoto | Canon Marketing Japan | N/A | |
Management Performance
Cross Country Healthcare Leadership Team
Elected by the shareholders, the Cross Country's board of directors comprises two types of representatives: Cross Country inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cross. The board's role is to monitor Cross Country's management team and ensure that shareholders' interests are well served. Cross Country's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cross Country's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen VargaSinka, Director Communications | ||
| James III, VP Officer | ||
| Gerald Purgay, Chief Officer | ||
| Joshua Vogel, VP Relations | ||
| MBA RN, Exec Officer | ||
| Colin MS, Chief Officer | ||
| Kevin Clark, CoFounder Chairman | ||
| John Martins, CEO Pres | ||
| Phillip Noe, Chief Officer |
Cross Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cross Country a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | |||
| Return On Asset | 0.21 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 1.18 B | |||
| Shares Outstanding | 36.82 M | |||
| Shares Owned By Insiders | 5.37 % | |||
| Shares Owned By Institutions | 99.85 % | |||
| Price To Earning | 6.82 X | |||
| Price To Book | 2.66 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Cross Stock
When determining whether Cross Country Healthcare offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cross Country's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cross Country Healthcare Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cross Country Healthcare Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Cross Country Healthcare. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.